highly significantp < 0.0001
However, treatment with NaBu during the transition span (21–42 days; Figure 2 ) yielded a highly significant increase in longevity ( p < 0.0001) at either dose.
However, treatment with NaBu during the transition span (21–42 days; Figure 2 ) yielded a highly significant increase in longevity ( p < 0.0001) at either dose.
At the low dose, an obvious but borderline significant ( p = 0.0589) shortening of the late life span is also noticed.